About this trial
Preeclampsia (PE) is an obstetric placental vascular pathology with a prevalence of 2 to 5% of pregnant women. It is defined by learned societies by the association of high blood pressure (BP≥140/90mmHg) and proteinuria \> 0.3g/day. The last French Maternal Mortality Report 2024 places cardiovascular complications among the main causes of maternal death. PE has an increasing number of deaths in 2016-2018 and significant preventability (66%).
Cesarean sections in pre-eclamptic patients are difficult procedures and, do not benefit from any specific recommendations. Cesarean section is promptly performed under regional anesthesia by spinal anesthesia or spinal anesthesia with combined epidural, techniques that cause maternal arterial hypotension with consequences for the baby.
These hypertensive patients, often on antihypertensives, challenge the anesthesiologist to manage the hemodynamic balance between the risk of arterial hypotension generated by the anesthesia corrected by vasoactive amines and the risk of major hypertension secondary to their management. The major risk in these patients with low platelet counts is hemorrhagic stroke.
Our study is an observational, bi-centric study between the maternity wards of the Clermont Ferrand and Lille University Hospitals.
It consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section.
The objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and/or hypertension through the implementation of non-invasive monitoring (ClearSight).
Patients meeting the inclusion and non-inclusion criteria may be included in the study by an investigator after having given a non-opposition agreement after having received clear and fair information about the study.
In any case, the care of patients participating in the study will not be modified in any way compared to the usual practices of the services.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pre-eclamptic patient according to the criteria defined by SFAR 2020.
Indication of organised or semi-urgent cesarean section (Green or Orange code).
Adult patient, benefiting from a social security system.
Oral non-opposition to participation in the study.
Disqualifiers
Urgent Cesarean (Red code).
Patient refusal.
Patient does not understand French.
Individual protection measures : guardianship, curatorship.
Trial population
Pre-eclamptic patients undergoing cesarean section in the maternity wards of the Clermont-Ferrand and Lille university hospitals
Trial design
Cohort
Prospective
Treatments tested in this trial
Observational study to evaluate professional practices
Other interventionIt consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section. The objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and/or hypertension through the implementation of non-invasive monitoring (ClearSight).
Treatment groups
Trial outcomes
Primary outcomes
Hemodynamic events.
Prevalence of the occurrence of events such as maternal arterial hypotension and/or arterial hypertension during a cesarean section in a known pre-eclamptic patient.
Secondary outcomes
Duration of maternal hypotensive or hypertensive episodes.
Defined by the time-weighted average intraoperative PAS below a threshold of 110mmHg or above a threshold of 170mmHg. This measurement is commonly called TWA (Time Weighted Average), corresponding to the area between the chosen PAS threshold and the measured PAS curve, divided by the total measurement time.
Number of maternal hypotensive and/or hypertensive episodes.
Occurrence of major adverse events.
Nature and dose of local anesthetic administered
Other outcomes
Maximum dosages and cumulative doses of Noradrenaline during cesarean section.
Total vascular filling volume.
Total diuresis.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Clermont-Ferrand
Lead sponsor
University Hospital, Lille
Collaborator
This trial is not recruiting at the moment. You can still explore other options: